Seer (SEER) to Release Quarterly Earnings on Wednesday

Seer (NASDAQ:SEER) will likely be announcing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect the company to announce earnings of ($0.27) per share and revenue of $3.55 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:30 PM ET.

Seer (NASDAQ:SEER) last announced its earnings results on Wednesday, May 13th. The company reported ($0.30) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.30). Seer had a negative return on equity of 26.58% and a negative net margin of 464.78%.The business had revenue of $2.79 million during the quarter, compared to analyst estimates of $3.60 million.

Seer Stock Performance

Shares of SEER stock opened at $2.22 on Monday. Seer has a 52-week low of $1.55 and a 52-week high of $2.41. The firm has a market capitalization of $122.06 million, a P/E ratio of -1.79 and a beta of 1.59. The stock has a 50 day moving average price of $1.90 and a 200 day moving average price of $1.86.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on SEER shares. Canaccord Genuity Group initiated coverage on Seer in a research report on Monday, May 4th. They set a “buy” rating and a $4.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Seer in a report on Friday, July 17th. Finally, TD Cowen raised shares of Seer to a “strong-buy” rating in a research report on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Seer has an average rating of “Buy” and a consensus target price of $4.00.

Institutional Trading of Seer

Hedge funds have recently added to or reduced their stakes in the business. Occudo Quantitative Strategies LP purchased a new position in Seer during the 2nd quarter valued at about $25,000. Marshall Wace LLP bought a new position in shares of Seer during the fourth quarter valued at approximately $85,000. Quadrature Capital Ltd purchased a new position in Seer during the fourth quarter valued at approximately $101,000. Barclays PLC increased its holdings in Seer by 685.0% during the fourth quarter. Barclays PLC now owns 60,717 shares of the company’s stock valued at $111,000 after buying an additional 52,982 shares during the period. Finally, Corient Private Wealth LLC bought a new position in Seer in the fourth quarter worth approximately $116,000. 75.20% of the stock is owned by hedge funds and other institutional investors.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.